Top

Published in:

15-12-2023 | Artificial Intelligence

Assessment of Prostate and Bladder Cancer Genomic Biomarkers Using Artificial Intelligence: a Systematic Review

Authors: Andrey Bazarkin, Andrey Morozov, Alexander Androsov, Harun Fajkovic, Juan Gomez Rivas, Nirmish Singla, Svetlana Koroleva, Jeremy Yuen-Chun Teoh, Andrei V. Zvyagin, Shahrokh François Shariat, Bhaskar Somani, Dmitry Enikeev

Published in: Current Urology Reports | Issue 1/2024

Abstract

Purpose of Review

The aim of the systematic review is to assess AI’s capabilities in the genetics of prostate cancer (PCa) and bladder cancer (BCa) to evaluate target groups for such analysis as well as to assess its prospects in daily practice.

Recent Findings

In total, our analysis included 27 articles: 10 articles have reported on PCa and 17 on BCa, respectively. The AI algorithms added clinical value and demonstrated promising results in several fields, including cancer detection, assessment of cancer development risk, risk stratification in terms of survival and relapse, and prediction of response to a specific therapy. Besides clinical applications, genetic analysis aided by the AI shed light on the basic urologic cancer biology. We believe, our results of the AI application to the analysis of PCa, BCa data sets will help to identify new targets for urological cancer therapy.

Summary

The integration of AI in genomic research for screening and clinical applications will evolve with time to help personalizing chemotherapy, prediction of survival and relapse, aid treatment strategies such as reducing frequency of diagnostic cystoscopies, and clinical decision support, e.g., by predicting immunotherapy response. These factors will ultimately lead to personalized and precision medicine thereby improving patient outcomes.

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global cancer observatory: cancer today. Lyon: International Agency for Research on Cancer; 2020. https://gco.iarc.fr/today. Accessed Feb 2021.

Van Booven DJ, et al. A Systematic Review of Artificial Intelligence in Prostate Cancer. 2021;31–39.

Hamet P, Tremblay J. Artificial intelligence in medicine. Metabolism. 2017;69:S36–40. https://doi.org/10.1016/j.metabol.2017.01.011.CrossRef

Haug CJ, Drazen JM. Artificial Intelligence and Machine Learning in Clinical Medicine, 2023. N Engl J Med. 2023;388(13):1201–8. https://doi.org/10.1056/NEJMra2302038.CrossRefPubMed

Hosein S, Reitblat CR. Clinical applications of artificial intelligence in urologic oncology. 2020;30(6):748–753. https://doi.org/10.1097/MOU.0000000000000819.

Dias R, Torkamani A. Artificial intelligence in clinical and genomic diagnostics. Genome Med. 2019;11(1). https://doi.org/10.1186/S13073-019-0689-8.

Phillips B, et al. Levels of Evidence, Oxford Centre for Evidence-based Medicine; 2011.

Li R, Dong X, Ma C, Liu L. Computational identification of surrogate genes for prostate cancer phases using machine learning and molecular network analysis. Theor Biol Med Model. 2014;11(1):1–12. https://doi.org/10.1186/1742-4682-11-37.CrossRef

Elmarakeby HA, et al. Biologically informed deep neural network for prostate cancer discovery. Nature. 2021;598(7880):348–52. https://doi.org/10.1038/s41586-021-03922-4.CrossRefPubMedPubMedCentral

10.

Dong H, Wang X. Identification of Signature Genes and Construction of an Artificial Neural Network Model of Prostate Cancer. J Healthc Eng. 2022;2022. https://doi.org/10.1155/2022/1562511.

11.

• Wang C, Li J. A deep learning framework identifies pathogenic noncoding somatic mutations from personal prostate cancer genomes. Cancer Res. 2021;80(21):4644–54. https://doi.org/10.1158/0008-5472.CAN-20-1791. The only article in the observed area related to noncoding alterations on cancer adverse clinical manifestation.CrossRef

12.

• Lee S, Kerns S, Ostrer H, Rosenstein B, Deasy JO, Oh JH. Machine Learning on a Genome-wide Association Study to Predict Late Genitourinary Toxicity After Prostate Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018;101(1):128–35. https://doi.org/10.1016/J.IJROBP.2018.01.054. Data presented about long-term outcomes of radiotherapy, including toxicity, depending on genes alterations.CrossRefPubMedPubMedCentral

13.

Hou Q, et al. RankProd Combined with Genetic Algorithm Optimized Artificial Neural Network Establishes a Diagnostic and Prognostic Prediction Model that Revealed C1QTNF3 as a Biomarker for Prostate Cancer. EBioMedicine. 2018;32:234–44. https://doi.org/10.1016/J.EBIOM.2018.05.010.CrossRefPubMedPubMedCentral

14.

Shamsara E, Shamsara J. Bioinformatics analysis of the genes involved in the extension of prostate cancer to adjacent lymph nodes by supervised and unsupervised machine learning methods: The role of SPAG1 and PLEKHF2. Genomics. 2020;112(6):3871–82. https://doi.org/10.1016/j.ygeno.2020.06.035.CrossRefPubMed

15.

Lin E, et al. Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. Oncologist. 2021;26(9):751–60. https://doi.org/10.1002/onco.13869.CrossRefPubMedPubMedCentral

16.

Weitz P, et al. Transcriptome-wide prediction of prostate cancer gene expression from histopathology images using co-expression-based convolutional neural networks. Bioinformatics. 2022;38(13):3462–9. https://doi.org/10.1093/BIOINFORMATICS/BTAC343.CrossRefPubMedPubMedCentral

17.

Lallous N, et al. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biol. 2016;17(1). https://doi.org/10.1186/S13059-015-0864-1.

18.

Bohl CE, Miller DD, Chen J, Bell CE, Dalton JT. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem. 2005;280(45):37747–54. https://doi.org/10.1074/JBC.M507464200.CrossRefPubMed

19.

Hoffman-Censits J, Kelly WK. Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer. Clin Cancer Res. 2013;19(6):1335–9. https://doi.org/10.1158/1078-0432.CCR-12-2910.CrossRefPubMed

20.

Pal SK, Stein CA, Sartor O. Enzalutamide for the treatment of prostate cancer. Expert Opin Pharmacother. 2013;14(5):679–85. https://doi.org/10.1517/14656566.2013.775251.CrossRefPubMed

21.

Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A. 2005;102(17):6201–6. https://doi.org/10.1073/PNAS.0500381102.CrossRefPubMedPubMedCentral

22.

Clegg NJ, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494–503. https://doi.org/10.1158/0008-5472.CAN-11-3948.CrossRefPubMedPubMedCentral

23.

Fizazi K, Smith MR, Tombal B. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. Clin Genitourin Cancer. 2018;16(5):332–40. https://doi.org/10.1016/J.CLGC.2018.07.017.CrossRefPubMed

24.

Snow O, Lallous N, Ester M, Cherkasov A. Deep learning modeling of androgen receptor responses to prostate cancer therapies. Int J Mol Sci. 2020;21(16):1–11. https://doi.org/10.3390/ijms21165847.CrossRef

25.

• Bartsch G, et al. Use of Artificial Intelligence and Machine Learning Algorithms with Gene Expression Profiling to Predict Recurrent Nonmuscle Invasive Urothelial Carcinoma of the Bladder. J Urol. 2016;195(2):493–8. https://doi.org/10.1016/j.juro.2015.09.090. The only article related to AI use in bladder cancer prognosis.CrossRefPubMed

26.

Borkowska EM, et al. Molecular subtyping of bladder cancer using Kohonen self-organizing maps. Cancer Med. 2014;3(5):1225–34. https://doi.org/10.1002/cam4.217.CrossRefPubMedPubMedCentral

27.

Dai ZT, et al. Prognostic Value of Members of NFAT Family For Pan-Cancer and a Prediction Model Based on NFAT2 in Bladder Cancer. Aging (Albany. NY). 2021;13(10):13876–13897. https://doi.org/10.18632/aging.202982.

28.

• Hu S, et al. Robust Prediction of Prognosis and Immunotherapy Response for Bladder Cancer through Machine Learning Algorithm,” Genes (Basel). 13(6). https://doi.org/10.3390/genes13061073. Complex and complete analysis of AI assessment of correlation between aberrant genes presence and response to immunotherapy.

29.

Mao XD, Chen SH, Li GH. Identification of a ten-long noncoding RNA signature for predicting the survival and immune status of patients with bladder urothelial carcinoma based on the GEO database: a superior machine learning model. Aging (Albany. NY). 2021;13(5):6957–6981. https://doi.org/10.18632/aging.202553.

30.

De Maturana EL, et al. Application of multi-SNP approaches Bayesian LASSO and AUC-RF to detect main effects of inflammatory-gene variants associated with bladder cancer risk. PLoS One. 2013;8(12). https://doi.org/10.1371/journal.pone.0083745.

31.

Zhou M, et al. Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer,” Brief Bioinform. 2021;22(3). https://doi.org/10.1093/bib/bbaa047.

32.

Catto JWF, et al. The Application of Artificial Intelligence to Microarray Data: Identification of a Novel Gene Signature to Identify Bladder Cancer Progression. Eur Urol. 2010;57(3):398–406. https://doi.org/10.1016/j.eururo.2009.10.029.CrossRefPubMed

33.

Ciaramella A, Di Nardo E, Terracciano D, Conte L, Febbraio F, Cimmino A. A new biomarker panel of ultraconserved long non-coding RNAs for bladder cancer prognosis by a machine learning based methodology. BMC Bioinformatics. 2023;23(Suppl):6. https://doi.org/10.1186/S12859-023-05167-6.CrossRef

34.

Yates DR, et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res. 2007;13(7):2046–53. https://doi.org/10.1158/1078-0432.CCR-06-2476.CrossRefPubMed

35.

Chen S, Zhang N, Wang T, Zhang E, Wang X., Zheng J. Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. Front Immunol. 2020;11. https://doi.org/10.3389/fimmu.2020.01900.

36.

Chen H, Yang W, Ji Z. Machine learning-based identification of tumor-infiltrating immune cell-associated model with appealing implications in improving prognosis and immunotherapy response in bladder cancer patients. Front Immunol. 2023;14. https://doi.org/10.3389/fimmu.2023.1171420.

37.

Wang Y, Chen L, Ju L, Xiao Y, Wang X. Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma. Int Immunopharmacol. 2020;87. https://doi.org/10.1016/j.intimp.2020.106818.

38.

Wang J, He X, Bai Y, Du G, Cai M. Identification and validation of novel biomarkers affecting bladder cancer immunotherapy via machine learning and its association with M2 macrophages. Front Immunol. 2022;13. https://doi.org/10.3389/fimmu.2022.1051063.

39.

Wang Y, et al. Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer. Cancer Med. 2020;9(20):7729–41. https://doi.org/10.1002/cam4.3400.CrossRefPubMedPubMedCentral

40.

Xu H, et al. Artificial intelligence-driven consensus gene signatures for improving bladder cancer clinical outcomes identified by multi-center integration analysis. Mol Oncol. 2022;16(22):4023–42. https://doi.org/10.1002/1878-0261.13313.CrossRefPubMedPubMedCentral

41.

Su PW, Sen Chen B. Systems Drug Design for Muscle Invasive Bladder Cancer and Advanced Bladder Cancer by Genome-Wide Microarray Data and Deep Learning Method with Drug Design Specifications. Int J Mol Sci. 2022;23(22). https://doi.org/10.3390/ijms232213869.

42.

Wan Q, Pal R. An Ensemble Based Top Performing Approach for NCI-DREAM Drug Sensitivity Prediction Challenge. PLoS One. 2014;9(6). https://doi.org/10.1371/journal.pone.0101183.

43.

Ma J, Sheridan RP, Liaw A, Dahl GE, Svetnik V. Deep Neural Nets as a Method for Quantitative Structure − Activity Relationships. 2015. https://doi.org/10.1021/ci500747n.

44.

Gui J, Li H. Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data. Bioinformatics. 2005;21(13):3001–8. https://doi.org/10.1093/bioinformatics/bti422.CrossRefPubMed

45.

Nakagawa H, Fujita M. Whole genome sequencing analysis for cancer genomics and precision medicine. Cancer Sci. 2018;109(3):513–22. https://doi.org/10.1111/cas.13505.CrossRefPubMedPubMedCentral

46.

•• Schwarze K, Buchanan J, Taylor JC, Wordsworth S. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med. 2018;20(10):1122–30. https://doi.org/10.1038/gim.2017.247. The article outlines the cost-effectiveness of whole-genome sequencing and thus helps to estimate the AI use in clinical practice and research.CrossRefPubMed

Title: Assessment of Prostate and Bladder Cancer Genomic Biomarkers Using Artificial Intelligence: a Systematic Review
Authors: Andrey Bazarkin
Andrey Morozov
Alexander Androsov
Harun Fajkovic
Juan Gomez Rivas
Nirmish Singla
Svetlana Koroleva
Jeremy Yuen-Chun Teoh
Andrei V. Zvyagin
Shahrokh François Shariat
Bhaskar Somani
Dmitry Enikeev
Publication date: 15-12-2023
Publisher: Springer US
Keywords: Artificial Intelligence
Prostate Cancer
Prostate Cancer
Published in: Current Urology Reports / Issue 1/2024
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-023-01193-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Assessment of Prostate and Bladder Cancer Genomic Biomarkers Using Artificial Intelligence: a Systematic Review

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content